1
Clinical Trials associated with Autologous CD30 CAR T Cell(New York Medical College)MAC-CAR: a Phase 1B/II Trial of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Autologous CD30+ CAR T Cells in Children, Adolescents and Young Adults with Poor-Risk Classical Hodgkin Lymphoma (cHL)
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
100 Clinical Results associated with Autologous CD30 CAR T Cell(New York Medical College)
100 Translational Medicine associated with Autologous CD30 CAR T Cell(New York Medical College)
100 Patents (Medical) associated with Autologous CD30 CAR T Cell(New York Medical College)
100 Deals associated with Autologous CD30 CAR T Cell(New York Medical College)